Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the target of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 1,780,000 shares, a growth of 8.5% from the October 15th total of 1,640,000 shares. Approximately 9.0% of the company's stock are short sold. Based on an average daily volume of 255,200 shares, the short-interest ratio is currently 7.0 days.

Candel Therapeutics Trading Down 11.6 %

Shares of NASDAQ CADL traded down $0.50 during mid-day trading on Friday, reaching $3.80. 628,283 shares of the company's stock were exchanged, compared to its average volume of 278,403. Candel Therapeutics has a 52-week low of $0.77 and a 52-week high of $14.30. The company's 50-day moving average is $6.06 and its 200-day moving average is $6.77. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.62 and a current ratio of 1.62.

Insider Buying and Selling at Candel Therapeutics

In other news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $6.05, for a total value of $90,750.00. Following the completion of the sale, the insider now directly owns 944,873 shares in the company, valued at $5,716,481.65. This represents a 1.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 31,800 shares of company stock valued at $193,380. Company insiders own 41.60% of the company's stock.

Hedge Funds Weigh In On Candel Therapeutics

Several institutional investors have recently modified their holdings of the business. State Street Corp lifted its position in Candel Therapeutics by 4.1% in the third quarter. State Street Corp now owns 492,005 shares of the company's stock valued at $3,410,000 after acquiring an additional 19,207 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Candel Therapeutics by 12.8% in the 3rd quarter. Geode Capital Management LLC now owns 448,997 shares of the company's stock worth $3,112,000 after acquiring an additional 51,111 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Candel Therapeutics during the 2nd quarter worth $338,000. Barclays PLC grew its stake in shares of Candel Therapeutics by 327.1% during the 3rd quarter. Barclays PLC now owns 28,688 shares of the company's stock worth $199,000 after purchasing an additional 21,971 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Candel Therapeutics in the 2nd quarter valued at about $162,000. Institutional investors and hedge funds own 13.93% of the company's stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.